News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Speedel Holding AG Reports on Data Published at Hypertension 2008 Medical Congress



6/19/2008 2:40:09 PM

BASEL, SWITZERLAND and BRDGEWATER, NJ--(Marketwire - June 19, 2008) - Speedel Holding Ltd. (SWX: SPPN) today announced that data for two of its developmental product candidates were presented at Hypertension 2008, the joint meeting of the International Society of Hypertension (ISH) and the European Society of Hypertension (ESH) in Berlin (14- 19 June 2008). Results from the Phase IIa proof-of-concept trial with SPP635, one of the company's next generation of renin inhibitors, demonstrated strong efficacy and good safety[2],[3]. Based on these results Speedel continues Phase IIa development in a special population of diabetic patients with mild-to-moderate hypertension. For SPP301, an endothelin receptor A antagonist in development for patients with diabetes, results of several pre-clinical investigations were presented[4],[5],[6].

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES